Scarica l'app Stockscreener
12.71
0.97%
0.14
Precedente Chiudi:
$12.57
Aprire:
$12.6
Volume 24 ore:
428.98K
Relative Volume:
0.26
Capitalizzazione di mercato:
$815.33M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-2.7216
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
+4.03%
1M Prestazione:
+4.20%
6M Prestazione:
+61.27%
1 anno Prestazione:
-29.49%
Intervallo 1D:
$12.50
$13.10
Intervallo di 1 settimana:
$11.82
$13.19
Portata 52W:
$5.90
$20.38
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
12.70 | 807.30M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.19 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.04 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
New nanoparticle technology offers hope for hard-to-treat diseases - GlobeNewswire Inc.
Trading Systems Reacting to (ARVN) Volatility - Stock Traders Daily
Nordea Investment Management AB Grows Position in Arvinas, Inc. $ARVN - MarketBeat
Breakout Move: Can Arvinas Inc grow without external fundingJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Arvinas, Inc. $ARVN Stock Position Boosted by Campbell & CO Investment Adviser LLC - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 27.9% in December - MarketBeat
Metastatic Prostate Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart.com
Short Squeeze: Will Arvinas Inc stock gain from government policies2025 Institutional Moves & Precise Swing Trade Alerts - Bộ Nội Vụ
TAC to the future: Where induced proximity is pointing in 2026 - BioCentury
Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Yahoo Finance
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug - MSN
Can Arvinas Inc. stock sustain institutional interestWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Why Arvinas Inc. stock remains on buy lists2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
How Arvinas Inc. (ARVN) Affects Rotational Strategy Timing - Stock Traders Daily
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - sharewise.com
Is Arvinas Inc. stock positioned well for digital economyPortfolio Return Report & Capital Efficiency Focused Ideas - ulpravda.ru
Movement Recap: Why Arvinas Inc. stock remains resilient2025 AllTime Highs & Expert Verified Movement Alerts - Улправда
Will Arvinas Inc. stock remain a Wall Street favoriteJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - Улправда
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Sentiment Watch: Is Arvinas Inc. stock positioned for long term growthTrade Analysis Report & Risk Managed Investment Strategies - Улправда
Citigroup upgrades Arvinas (ARVN) - MSN
Citigroup Upgrades Arvinas (ARVN) - Nasdaq
Arvinas (NASDAQ:ARVN) Shares Gap UpTime to Buy? - MarketBeat
ARVN Stock: Citigroup Upgrades Arvinas to 'Buy' with 50% Target - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Down 2.6%Should You Sell? - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Aug Patterns: Will Arvinas Inc stock remain a Wall Street favorite2025 Top Gainers & Safe Investment Capital Preservation Plans - moha.gov.vn
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the Biotechnology Frontier with PROTAC Innovation - DirectorsTalk Interviews
Aug Closing: Is Arvinas Inc stock ready for breakoutEntry Point & Consistent Return Investment Signals - moha.gov.vn
(ARVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas announces preclinical data for ARV-393 - MSN
Will Arvinas Inc. stock deliver better than expected guidanceEarnings Recap Report & Reliable Volume Spike Alerts - Улправда
(ARVN) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st
Barclays maintains Arvinas (ARVN) overweight recommendation - MSN
Barclays Raises Price Target for Arvinas (ARVN) to $18 | ARVN St - GuruFocus
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN - MarketBeat
Armistice Capital LLC Invests $4.12 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc (NASDAQ:ARVN) Nasdaq Composite Biotech Innovation - Kalkine Media
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Velan Capital Investment Management LP Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Diadema Partners LP Invests $710,000 in Arvinas, Inc. $ARVN - MarketBeat
Arvinas reveals promising preclinical data for ARV-393 - MSN
Arvinas Reveals Promising Preclinical Data for ARV-393 - TipRanks
Arvinas, Inc. Announces Preclinical Data for ARV-393 Combination - TradingView
22NW LP Acquires Shares of 413,533 Arvinas, Inc. $ARVN - MarketBeat
Arvinas (ARVN) Reveals Promising Preclinical Data for Cancer Tre - GuruFocus
Published on: 2025-12-06 23:24:37 - BỘ NỘI VỤ
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - The Manila Times
Arvinas, Inc. Announces Phase 1 Clinical Trial Initiation for ARV-393 Plus Glofitamab in Diffuse Large B-Cell Lymphoma Following Promising Preclinical Data - Quiver Quantitative
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.31%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):